Advertisement

USFDA Completes Pre-approval Inspection Of Bajaj Healthcare's Vadodra Facility

The pre-approval inspection of USFDA has been completed successfully with ZERO 483 observations of the manufacturing facilities of Bajaj Healthcare, the company's statement read

Bajaj Healthcare a manufacturer of APIs (Active Pharmaceutical Ingredients), Intermediates and Formulations, said that the United State Food and Drug Administration (USFDA) has completed pre-approval inspection of its API facility located at Vadodara, Gujarat.

USFDA conducted its pre-approval inspection of Bajaj Healthcare's API facility located at Vadodara, Gujarat from November 14, 2022, to November 17, 2022. 

"The pre-approval inspection of USFDA has been completed successfully with ZERO 483 observations of the manufacturing facilities of Bajaj Healthcare," the company's statement read.

Commenting on this, Anil Jain, Joint Managing Director, Bajaj Healthcare said “I am happy to announce that we successfully completed first ever pre approval USFDA inspection with ZERO 483 observation at our API Manufacturing facilities located at Vadodara, Gujarat. We are committed to strict adherence to all applicable guidelines and regulations and maintaining the highest quality standards in delivering quality services and timely delivery to our clients.”


Tags assigned to this article:

Advertisement

Around The World